Toggle main navigation
News
Insights
Meetings
Multimedia
ASCO AI in Oncology
Search
Close
AI in Oncology
Bladder Cancer
Breast Cancer
Cardio-oncology
CNS Cancers
Colorectal Cancer
Cost of Care
Infectious Diseases
Gastrointestinal Cancer
Genomics/Genetics
Geriatric Oncology
Global Cancer Care
Gynecologic Cancers
Head and Neck Cancer
Health-Care Policy
Hepatobiliary Cancer
Immunotherapy
Kidney Cancer
Leukemia
Lung Cancer
Lymphoma
Multiple Myeloma
Myelodysplastic Syndromes
Neuroendocrine Tumors
Pancreatic Cancer
Prostate Cancer
Sarcoma
Skin Cancer
Survivorship
Thyroid Cancer
Solid Tumors
Hematologic Malignancies
Issues in Oncology
Gynecologic Cancers
Advertisement
The ASCO Post
Gynecologic Cancers
Gynecologic Cancers
Risovalisib Yields Highest Reported Monotherapy Response Rate in Ovarian Clear Cell Carcinoma
November 18
2 min read
In a phase II trial, risovalisib yielded a 35% objective response rate in patients with recurrent or persistent
PIK3CA
-mutated ovarian clear cell carcinoma.
Gynecologic Cancers
ROSELLA Subgroup Analysis Supports Relacorilant Use in Patients Previously Treated With Taxanes
November 10
6 min read
Gynecologic Cancers
First-Line Pembrolizumab Improves Progression-Free Survival in dMMR Advanced Endometrial Cancer
November 4
3 min read
Gynecologic Cancers
Neoadjuvant Niraparib Shows Activity in HRD-Positive Advanced Ovarian Cancer
November 3
3 min read
Gynecologic Cancers
ESMO 2026: Sacituzumab Tirumotecan vs Physician’s Choice of Treatment in Patients With Previously Treated Endometrial Cancer
October 28
3 min read
AI in Oncology
Machine Learning Models Outperform Traditional Approaches to Multicancer Risk Prediction
October 28
3 min read
Gynecologic Cancers
Immunotherapy/PARP Inhibitor Combination Prolongs Survival in Advanced Endometrial Cancer
October 27
2 min read
Latest in Gynecologic Cancers
Load More
Advertisement